open access

Vol 5, No 3 (2009)
Review paper
Published online: 2009-05-15
Get Citation

Metabolic syndrome - important cancer risk factor

Ewa Konduracka
Onkol. Prak. Klin 2009;5(3):99-102.

open access

Vol 5, No 3 (2009)
REVIEW ARTICLES
Published online: 2009-05-15

Abstract

Metabolic syndrome is defined as a combination of lipids disorders and cardiovascular risk factors: abdominal obesity, insulin resistance, arterial hypertension or high normal blood pressure. The positive relationships between majority of components of metabolic syndrome and development of some types of cancer was shown in several studies. This fact is often forgotten in our daily medical practice. The crucial mechanisms of oncogenesis in patients with metabolic syndrome include mitogenic influence of insulin with induction of cell proliferation, its pathological growth and differentation. It is also well known that insulin acts as apoptosis inhibitor preventing the destruction of neoplastic cells. Furthermore abdominal obesity was shown to be an important risk factor of carcinogenesis. Its pathogenic action is based on active peptides and proteins relisae which are linked with the atherosclerosis, inflammation, endothelium dysfunction and oncogenesis. Therefore treatment of metabolic syndrome as a prevention of some types of cancer should concentrate on improvement in insulin sensitivity by means of body mass reduction, increased physical activity, aprpopriate full of fibers diet, natural antyoxidants and also early administration of metformine. Patients with metabolic syndrom, as the population with significantly increased risk of cancer, should be includedd in dedicated prevention programmas.

Abstract

Metabolic syndrome is defined as a combination of lipids disorders and cardiovascular risk factors: abdominal obesity, insulin resistance, arterial hypertension or high normal blood pressure. The positive relationships between majority of components of metabolic syndrome and development of some types of cancer was shown in several studies. This fact is often forgotten in our daily medical practice. The crucial mechanisms of oncogenesis in patients with metabolic syndrome include mitogenic influence of insulin with induction of cell proliferation, its pathological growth and differentation. It is also well known that insulin acts as apoptosis inhibitor preventing the destruction of neoplastic cells. Furthermore abdominal obesity was shown to be an important risk factor of carcinogenesis. Its pathogenic action is based on active peptides and proteins relisae which are linked with the atherosclerosis, inflammation, endothelium dysfunction and oncogenesis. Therefore treatment of metabolic syndrome as a prevention of some types of cancer should concentrate on improvement in insulin sensitivity by means of body mass reduction, increased physical activity, aprpopriate full of fibers diet, natural antyoxidants and also early administration of metformine. Patients with metabolic syndrom, as the population with significantly increased risk of cancer, should be includedd in dedicated prevention programmas.
Get Citation

Keywords

metabolic syndrome; abdominal obesity; cancer

About this article
Title

Metabolic syndrome - important cancer risk factor

Journal

Oncology in Clinical Practice

Issue

Vol 5, No 3 (2009)

Article type

Review paper

Pages

99-102

Published online

2009-05-15

Bibliographic record

Onkol. Prak. Klin 2009;5(3):99-102.

Keywords

metabolic syndrome
abdominal obesity
cancer

Authors

Ewa Konduracka

References (20)
  1. Alberti K, Zimmet P, Shaw J. The metabolic syndrome—a new worldwide definition. The Lancet. 2005; 366(9491): 1059–1062.
  2. Russo A, Autelitano M, Bisanti L. Metabolic syndrome and cancer risk. Eur J Cancer. 2008; 44(2): 293–297.
  3. Bergström A, Pisani P, Tenet V, et al. Overweight as an avoidable cause of cancer in Europe. Int J Cancer. 2001; 91(3): 421–430.
  4. Henderson K, Bernstein L. Etiology of cancer: obesity and physical activity. In: De Vita V, Lawrence T, Rosenberg S, Weinberg R, De Pinho R. ed. Cancer. Principles and Practice of Oncology. Lippincott Williams & Wilkins, Philadelphia 2008: 243–250.
  5. Ulen CH, Huizinga M, Beech B, et al. Zapobieganie ponownemu wzrostowi masy ciała. Diabetologia po Dyplomie. 2008; 5: 57–68.
  6. Hjartåker A, Langseth H, Weiderpass E. Obesity and diabetes epidemics: cancer repercussions. Adv Exp Med Biol. 2008; 630: 72–93.
  7. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003; 348(17): 1625–1638.
  8. Schäffler A, Müller-Ladner U, Schölmerich J, et al. Role of adipose tissue as an inflammatory organ in human diseases. Endocr Rev. 2006; 27(5): 449–467.
  9. Schiel R, Beltschikow W, Steiner T, et al. Diabetes, insulin, and risk of cancer. Methods Find Exp Clin Pharmacol. 2006; 28(3): 169–175.
  10. Giovannucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr. 2007; 86(3): s836–s842.
  11. Diabetes mellitus and cancer. Eur J Intern Med. 2000; 11(5): 245–252.
  12. Lahmann PH, Schulz M, Hoffmann K, et al. Long-term weight change and breast cancer risk: the European prospective investigation into cancer and nutrition (EPIC). Br J Cancer. 2005; 93(5): 582–589.
  13. Giovannucci E, Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology. 2007; 132(6): 2208–2225.
  14. Morita T, Tabata S, Mineshita M, et al. The metabolic syndrome is associated with increased risk of colorectal adenoma development: the Self-Defense Forces health study. Asian Pac J Cancer Prev. 2005; 6(4): 485–489.
  15. Hojo M, Nagahara A, Miyazaki A, et al. Metabolic syndrome and gastrointestinal diseases. J Gastroenterol. 2007; 42(4): 267–274.
  16. Limburg P, Anderson K, Johnson T, et al. Diabetes mellitus and subsite-specific colorectal cancer risks in the Iowa Women's Health Study. Cancer Epidemiol. Biomarkers Prev. 2005; 14: 133–137.
  17. Nagel JM, Bücker S, Wood M, et al. [Colorectal carcinoma screening in patients with type 2 diabetes mellitus]. Z Gastroenterol. 2006; 44(11): 1153–1165.
  18. Bowker SL, Majumdar SR, Veugelers P, et al. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006; 29: 1990–1991.
  19. Evans JMM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005; 330(7503): 1304–1305.
  20. Schiel R, Müller UA, Braun A, et al. Risk of malignancies in patients with insulin-treated diabetes mellitus: results of a population-based trial with 10-year follow-up (JEVIN). Eur J Med Res. 2005; 10(8): 339–344.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl